Continued zidovudine or didanosine for human immunodeficiency virus infection.

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.

Didanosine therapy in patients intolerant of or failing zidovudine therapy.

Zidovudine for prophylaxis of human immunodeficiency virus infection after accidental exposure.

Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine.

Use of zidovudine following occupational exposure to human immunodeficiency virus.

Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine.

Zidovudine in the treatment of human immunodeficiency virus disease.

A survey of zidovudine use in pregnant women with human immunodeficiency virus infection.

A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection.

Zidovudine after occupational exposure to the human immunodeficiency virus.

Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.

Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection.

Didanosine for zidovudine-intolerant patients with HIV disease.

Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.

Continued monitoring for human immunodeficiency virus type 2 infections in California.

[Microbiological diagnosis of human immunodeficiency virus infection].

Microbiome in human immunodeficiency virus infection.

Human immunodeficiency virus infection and pneumothorax.

Suggest Documents

A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.

Didanosine therapy in patients intolerant of or failing zidovudine therapy.

Zidovudine for prophylaxis of human immunodeficiency virus infection after accidental exposure.

Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

Combined treatment of symptomatic human immunodeficiency virus type 1 infection with native interferon-alpha and zidovudine.

Use of zidovudine following occupational exposure to human immunodeficiency virus.

Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine.

Zidovudine in the treatment of human immunodeficiency virus disease.

A survey of zidovudine use in pregnant women with human immunodeficiency virus infection.

A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection.

Zidovudine after occupational exposure to the human immunodeficiency virus.

Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.

Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection.

Didanosine for zidovudine-intolerant patients with HIV disease.

Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.

Continued monitoring for human immunodeficiency virus type 2 infections in California.

[Microbiological diagnosis of human immunodeficiency virus infection].

Microbiome in human immunodeficiency virus infection.

Human immunodeficiency virus infection and pneumothorax.

Continued zidovudine or didanosine for human immunodeficiency virus infection.

Recommend Documents

Follow Us